U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 10-Q
 Mark One
[ X]  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934

For the period ended June 30, 2009

[   ]  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934

For the transition period from ______ to _______
  Commission File No. 000-52703
 
 Genova Biotherapeutics Inc.
(Name of small business issuer in its charter)Nevada
(State or other jurisdiction of incorporation
or organization)
20-4939361
(I.R.S. Employer Identification No.)1461 A. First Avenue, Suite 360 New York, NY
(Address of principal executive offices)Kinder Travel Inc.
1461 A. First Avenue, Suite 360 New York, NY
(Name and address if changed from prior report)(646) 845-1920
(Issuer’s telephone number)Securities registered pursuant to Section
12(b) of the Act:
Name of each exchange on which
registered:NoneSecurities registered pursuant to Section 12(g) of the Act:Common Stock, $0.001(Title of Class)
  Indicate by checkmark whether the issuer: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes
[X ]   No[    ]
   Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (Section 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was
required to submit and post such files. Yes [   ]    No[   ]    N/A [X ]
   Table of Contents
 1
 Indicate by check mark whether the registrant is a large accelerated filed, an accelerated filer, a non-accelerated filer, or a smaller reporting company.
   Large accelerated filer [  ]                                                                           Accelerated
filer [   ]
   Non-accelerated filer [   ]                                                                           Smaller
reporting company [X]
   Indicate by checkmark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [   ]  No [X]
   Applicable Only to Issuer Involved in Bankruptcy Proceedings During the Preceding Five Years. N/A
   Indicate by checkmark whether the issuer has filed all documents and reports required to be filed by Section 12, 13 and 15(d) of the Securities Exchange Act of 1934 after the distribution of securities under a plan confirmed by a court.  Yes[   ]  No[   ]    N/A [X ]
   Applicable Only to Corporate Registrants
   Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the most practicable date:
 
  Class
Outstanding as of  August 10, 2009Common Stock, $0.001
307,296,125
   Table of Contents
 2
  
 Genova Biotherapeutics, Inc.(Formerly known as Kinder Travel Inc.)Table of Contents
 
 PagePart 1.
FINANCIAL INFORMATIONItem 1.
Financial Statements
4Item 2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
9Item 3.
Quantitative and Qualitative Disclosures About Market Risk
14Item 4.
Controls and Procedures
14Part II.
OTHER INFORMATIONItem 1.
Legal Proceedings
15Item 1A.
Risk Factors
15Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
16Item 3.
Defaults Upon Senior Securities
16Item 4.
Submission of Matters to a Vote of Security Holders
16Item 5.
Other Information
17Item 6.
Exhibits
18
 
  Table of Contents
 3
 PART I
 
 ITEM 1. FINANCIAL STATEMENTS
   Genova Biotherapeutics, Inc.(Formerly known as Kinder Travel Inc.)Balance Sheets(In Canadian Dollars)June 30, 2009

December 31, 2008ASSETS

(Unaudited)Current AssetsCash
$
28,884
$
21,220Accounts receivable, net of allowance for doubtful accounts

6,165

-Total Current Assets

35,049

21,220Other AssetsIntellectual Property - Medical Patents

92,573

-Vehicles and Equipment, net of accumulated depreciation

16,467

21,957Website, net of accumulated depreciation

592

1,777Travel Agency Bond

15,000

15,000Total Other Assets

124,632

38,734TOTAL ASSETS
$
159,681
$
59,954LIABILITIESCurrent LiabilitiesAccounts payable
$
45,239
$
37,157Accrued liabilities

2,906

4,286Payroll Liabilities

2,470

2,085Sales Tax Payable

613

105Customer Prepayments

-

310Shareholders' Loans

41,759

31,273Current Portion of long-term debt

19,860

1,136Total Current Liabilities

112,847

76,352Long Term LiabilitiesLoan payable

-

19,282Total Long Term Liabilities

-

19,282TOTAL LIABILITIES

112,847

95,634STOCKHOLDERS’ EQUITY (DEFICIT)Capital StockPreferred StockAuthorized:  10,000,000 shares with $0.00001 par value.      Issued: Nil

-

-Common StockAuthorized: 990,000,000 common shares with $0.00001 par valueIssued: 331,250,000 (Jun 30/09); 300,000,000 (Dec 31/08)

3,750

3,364Additional paid-in capital

223,036

129,436Accumulated Other Comprehensive Income

848

(855)Retained Earnings
(180,800)

(167,625)TOTAL STOCKHOLDERS' EQUITY (DEFICIT)

46,834

(35,680)TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
$
159,681
$
59,954The accompanying notes are an integral part of these consolidated financial statements.
 
  Table of Contents
 4
  Genova Biotherapeutics, Inc.(Formerly known as Kinder Travel Inc.)Unaudited Statements of Operations(In Canadian Dollars)For the Three

For the Three

For the Six

For the SixMonths Ended

Months Ended

Months Ended

Months EndedJune 30, 2009

June 30, 2008

June 30, 2009

June 30, 2008Sales
$
58,851
$
67,860
$
125,698
$
139,405Cost of Sales

22,553

17,447

55,517

32,148Gross Margin

36,298

50,413

70,181

107,258General and Administrative ExpensesAutomobile Expense

3,941

3,314

7,822

6,663Depreciation and Amortization

3,337

2,387

6,675

4,773General and Administrative

8,460

19,012

14,564

32,258Payroll Expenses

15,026

27,094

27,970

54,785Professional Fees

8,949

1,608

14,055

9,780Transfer Agent Fees

11,752

-

12,270

-Total Expenses

51,465

53,414

83,356

108,259Profit (Loss) from Operations

(15,167)

(3,001)

(13,175)

(1,002)Provision for Income Tax

0

0

0

-Net Operating Profit (Loss)
$
(15,167)
$
(3,001)
$
(13,175)
$
(1,002)Comprehensive Income(Loss)Net Profit (Loss)
(15,167)

(3,001)

(13,175)

(1,002)Foreign currency translation adjustment
1,607

(617)

1,703

(411)Total Comprehensive Income(Loss)
$
(13,560)
$
(3,618)
$
(11,472)
$
(1,412)$
(0.00)
$
(0.00)
$
(0.00)
$
(0.00)Gain (Loss) per Share – Basic and Diluted326,098,901

300,000,000

313,121,547

300,000,000Weighted Average Shares OutstandingThe accompanying notes are an integral part of these consolidated financial statements.
  Table of Contents
 5
  Genova Biotherapeutics, Inc.(Formerly known as Kinder Travel Inc.)Unaudited Statements of Cash Flows(In Canadian Dollars)For the Six Months Ended                   June 30, 2009

For the Six Months Ended                   June 30, 2008OperatingNet Income (Loss)
$
(13,175)
$
(1,002)Adjustments to reconcile net income (loss) to net cash flows used in operating activitiesDepreciation and Amortization

6,675

4,773Imputed interest of shareholders loans

1,413

-Changes in operating assets and liabilitiesAccounts receivable

(6,165)

(19,013)Prepaid Expenses

0

2,682Accounts payable

8,082

1,880Accrued liabilities

(1,380)

-Payroll Liabilities

385

-Sales Tax Payable

508

-Customer Prepayments

(310)

-Net cash flows from (used for) operations

(3,967)

(10,680)FinancingBorrowings on debt

19,907

113,135Payments on debt

(9,979)

(104,040)Net cash flows from financing activities

9,928

9,096Effect of exchange rate changes

1,703

(411)Change in Cash

7,664

(1,995)Cash - Beginning

21,220

16,275Cash - Ending
$
28,884
$
14,280Supplemental Cash Flow InformationCash paid for:Income Taxes
$
-
$
-Interest
$
-
$
-Non Cash TransactionsStock issued to acquire patents
$
92,573
$
-
 The accompanying notes are an integral part of these consolidated financial statements.
   Table of Contents
 6
 Genova Biotherapeutics, Inc.(Formerly known as Kinder Travel Inc.)Unaudited Notes to the Financial Statements(In Canadian Dollars)
 
 Note 1 – Description of Business
 Genova Biotherapeutics, Inc. (the "Company") was incorporated under the laws of the state of Nevada as Kinder Travel Inc.  The Company changed its name on April 24, 2009.
 
 The Company is a biotechnological drug development company with a focus on identifying, evaluating and acquiring new promising drugs for treatment and prevention of oncological and infectious diseases in human beings.  Prior to that, the Company was a full-service travel agency, offering the full range of travel services including
corporate travel, vacations, cruise holidays, and group tours.
 
 On April 20, 2009, the Company acquired the right, title and interest in three medical patents for the treatment of prostate and breast cancers. This transaction is explained in detail in Note 7.
 
 Effective July 1, 2009, the Company disposed of its travel related business assets. See Note 9.
 
 Note 2 – Basis of Presentation
 The accompanying unaudited interim consolidated financial statements of Genova Biotherapeutics, Inc. have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission, and should be read in conjunction with the Company’s audited
2008 annual financial statements and notes thereto filed with the SEC on form 10-K. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the result of operations for the interim periods presented have been reflected herein. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements which would substantially duplicate
the disclosure required in the Company’s 2008 annual financial statements have been omitted.
 
 Note 3 - Going Concern
 The Company’s financial statements have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities and commitments in the normal course of business for the foreseeable future. Since inception, the Company has accumulated losses aggregating to $180,800 and has insufficient working
capital to meet operating needs for the next twelve months as of June 30, 2009, all of which raise substantial doubt about the Company’s ability to continue as a going concern.
 
 Note 4 - Long-Term Debt
 The Company has a note payable to a bank. The note is secured by a vehicle, bears interest at 7.89% per year and requires monthly payments of $226 until June 2, 2010, at which time all remaining principal is due in full.
 
 Note 5 – Shareholder Loans
 As of June 30, 2009 and December 31, 2008, the total due to shareholders was $41,759 and $31,273, respectively. These loans are unsecured, non-interest bearing, and have no specific repayment terms. Imputed interest of $758 was calculated at a rate of 7.89% and recorded in additional paid-in capital at June 30, 2009.
 
 Note 6 – Related Party Transactions
 As of June 30, 2009, there are no related party transactions other than the shareholder loans.
 
 Note 7 - Acquisition of Medical Patents
 The Company approved the execution of an asset purchase agreement dated April 15, 2009 with Phoinos Oxford Lifesciences Limited, a company incorporated under the laws of the Federation of St. Kitts & Nevis, for the purchase of the right, title and interest in and to 3 medical patents. The patents will be amortized over its useful life
of 17 years. Amortization for the period ending June 30, 2009 is immaterial to the financial statements.
 
 Table of Contents
 7
 As payment, the Company placed in escrow an aggregate of 31,250,000 shares of its restricted common stock valued at $0.0024 USD per share, based on the trading price of the stock on April 15, 2009, for a total of $92,573 which will be subsequently transferred to the Phoinos Oxford Lifesciences Limited in ten (10) quarterly installments.
Phoinos Oxford Lifesciences Limited agreed to assign the voting rights of the Shares held in escrow to Global Developments Inc., an existing shareholder of the Company.
 
 On April 20, 2009, the due diligence by the Company and Seller was completed to the satisfaction of both parties and the Agreement was consummated. Therefore, on April 20, 2009, the right, title and interest to the Medical Patents was transferred by the Seller to the Company and the Company issued 31,250,000 shares of its resticted stock
for a total of $92,573 in the record name of Global Developments Inc., a Delaware corporation, as consideration for the patents.
 
 The 31,250,000 shares are being held by an escrow agent and 10% of the Shares will be transferred quarterly from Global Developments Inc. to Phoinos Oxford Lifesciences Limited in accordance with the terms of the Agreement.
 
 Note 8 – Share Capital
 
 1.
On April 20, 2009, the Company issued 31,250,000 common shares at $0.0024 per share for the purchase of the rights, title, and interest in 3 medical patents pursuant to an Asset Purchase Agreement dated April 15, 2009.
 
 2.
On April 24, 2009, the authorized share capital of the company was increased from 65,000,000 shares, par value of $0.001, to 990,000,000 shares, par value $0.00001. All share capital and paid-in capital amounts have been retroactively adjusted for all periods to reflect this change in par value.
 
 Note 9 - Subsequent events
 
 1.
On July 13, 2009, the Company’s completed a 125-for-1 forward stock split of the issued and outstanding common stock. These financial statements reflect the effects of this forward stock split.
 
 2.
On July 20, 2009, Dirk Holzhauer, a director and former officer of the Company, retired 23,953,875 shares of his common stock of the Company to acquire the Company’s travel related business assets effective July 1, 2009 pursuant to an Asset Purchase Agreement dated April 20, 2009.
  Table of Contents
 8
 ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
 
 GENERAL
 
 Genova Biotherapeutics Inc. is a corporation organized under the laws of the State of Nevada in December 2005. Initial operations commenced under the name “Kinder Travel & Tours” as a sole proprietorship in January 2005. In November 2005, Kinder Travel & Tours was incorporated under the laws of the Province of British
Columbia as Kinder Travel, Inc. (“KTBC”). On December 6, 2005, Kinder Travel Inc. was incorporated under the laws of the State of Nevada. Subsequently, pursuant to the terms and provisions of an asset purchase agreement (the “Asset Purchase Agreement”) with KTBC, we acquired all of the assets and liabilities of KTBC in exchange for a convertible note of $20,000 (the “Note”). The Note was subsequently distributed to KTBC’s sole shareholder, Dirk Holzhauer, who converted
the Note into 400,000 shares of our restricted common stock. After the effective date of our registration statement filed with the Securities and Exchange Commission (February 2, 2007), we commenced trading on the Over-the-Counter Bulletin Board under the symbol “KNDT:OB” on approximately July 3, 2007.
 
 From inception, Kinder Travel Inc. had been a travel agency offering a full range of travel services including corporate travel, vacations, cruise holidays, and group tours. Since Kinder Travel Inc. was incurring continued losses in the travel industry, the Board of Directors decided it was in the best interests of the Corporation to pursue
other business opportunities. Through his past contacts in the bio-medical industry, the then President of Kinder Travel Inc. initiated negotiations with Phoinos Oxford Lifesciences Limited, a company incorporated under the laws of the Federation of St. Kitts & Nevis (“Phoinis Oxford”), for the purchase of medical patents for the treatment of prostate and breast cancers.  On April 15, 2009, Kinder Travel Inc. entered into an asset purchase agreement dated April 15, 2009 (the “Asset
Purchase Agreement”) with Phoinos Oxford.
 
 The Company subsequently changed its to “Genova Biotherapeutics Inc.” Our shares of common stock now trade on the Over-the-Counter Bulletin Board under the symbol “GVBP.OB”.
 
 Please note that throughout this Quarterly Report, and unless otherwise noted, the words "we," "our," "us," the "Company," or "Kinder Travel," refers to Genova Biotherapeutics Inc.
 
 RECENT CORPORATE DEVELOPMENTS
 
 Forward Stock Split
 
 On April 21, 2009, our Board of Directors pursuant to a Board of Directors meeting authorized and approved a forward stock split of one hundred and twenty five for one (125:1) of our total issued and outstanding shares of common stock (the “Forward Stock Split”).
 
 The Forward Stock Split was effectuated based on market conditions and upon a determination by our Board of Directors that the Forward Stock Split was in our best interests and of the shareholders. Certain factors were discussed among the members of the Board of Directors concerning the need for the Forward Stock Split, including the increased
potential for financing. The intent of the Forward Stock Split is to increase the marketability of our common stock.
 
 The Forward Stock Split was effectuated on July 13, 2009 upon filing the appropriate documentation with NASDAQ. The Forward Stock Split increased our total issued and outstanding shares of common stock from 2,650,000 to approximately 331,250,000 shares of common stock.
 
 Change in Corporate Name
 
 The Board of Directors approved a resolution on April 21, 2009 to amend our Articles of Incorporation to change our name from “Kinder Travel Inc.” to “Genova Biotherapeutics Inc”.  An amendment to our Articles of Incorporation was filed with the Nevada Secretary of State on April 24, 2009 effecting the
change in name from “Kinder Travel Inc. to “Genova Biotherapeutics Inc.”  See “Part II. Item 4. Submission of Matters to a Vote of Security Holders.”
 
 The objective of the change in our corporate name was deemed necessary to more accurately reflect our proposed business activities in our name. We believe that the change in our corporate name will better communicate to the public our proposed and future nature of business operations.
 
 Table of Contents
 9
 Increase in Authorized Capital Structure
 
 The Board of Directors approved a resolution on April 21, 2009 to amend our Articles of Incorporation to increase our authorized capital structure from 65,000,000 shares of common stock with a par value of $0.001 to 1,000,000,000 shares of common stock with a par value of $0.00001 per share (the “Change in Capital Structure”).
An amendment to our Articles of Incorporation was filed with the Nevada Secretary of State on April 24, 2009 effecting the Change in Capital Structure. See “See “Part II. Item 4. Submission of Matters to a Vote of Security Holders.”
 
 The objective of the Change in Capital Structure was to allow for future issuances of our common stock in accordance with forward stock splits, proposed equity financings, debt settlement, and contractual provisions. Our Board of Directors believed that an increase in the authorized capital structure would increase our marketability and
liquidity in the future.
 
 Cancellation of Shares
 
 On July 20, 2009, our prior executive officer, Dirk Holzhauer, agreed to return an aggregate 23,953,875 shares of our common stock. Mr. Holzhauer agreed to return the shares of common stock to us in return for the acquisition of our travel related business assets. See “Current Business Operations” below.
 
 CURRENT BUSINESS OPERATIONS
 
 Our Board of Directors engaged in an analysis of the current travel industry including, but not limited to: (i) general economic conditions relating to travel; (ii) current appeal of websites to businesses and travelers to purchase significantly more travel products online than previously; (iii) growth of the usage of the Internet as a
medium of commerce for travel products; and (iv) current travel industry competition. Our Board of Directors determined that we would not grow as a business as expected within the travel industry. Therefore, our Board of Directors engaged in discussions and negotiations regarding a change in our strategic business operational planning. These discussions lead to a decision by our Board of Directors to divest and sell our travel related products and assets and acquire the right, title and interest in and to three
medical patents as described below.
 
 Asset Purchase Agreement
 
 In furtherance of strategic planning, our Board of Directors engaged in negotiations regarding a transaction in which we would acquire the right, title and interest in and to three separate medical patents (collectively, the “Medical Patents”), owned by Phoinos Oxford.
  Our Board of Directors approved the execution of the Asset Purchase Agreement with Phoinos Oxford.  Under the terms and provisions of the Asset Purchase Agreement and that certain escrow agreement dated April 15, 2009 between us and Phoinos Oxford (the “Escrow Agreement”): (i) we purchased the right, title and interest
in and to the Medical Patents for $92,573 (the “Purchase Price”); (ii) as payment of the Purchase Price for the Medical Patents, we placed in escrow an aggregate of 250,000 shares of our restricted common stock valued at $0.30 per share, as increased to 31,250,000 shares of common stock in accordance with the Forward Stock Split (the “Escrow Shares”), which Shares are to be subsequently transferred to Phoinos Oxford in ten (10) quarterly installments; and (iii) Phoinos Oxford agrees to
assign the voting rights of the Shares held in escrow to Global Developments Inc., one of our existing shareholders (“Global”). The Escrow Shares are being held by Global as escrow agent and 10% of the Escrow Shares will be transferred quarterly from Global to Phoinos Oxford in accordance with the terms of the Escrow Agreement. See “Part II. Item 2. Unregistered Sales of Securities and Use of Proceeds.”
 Table of Contents
 10
 The Agreement
 
 As discussed above, our Board of Directors was further engaged in discussions and negotiations regarding strategic business operational planning pertaining to a divesture and sale of our travel related products and assets including, but not limited to, suppliers list, customer and vendor lists, records, tradename, trademark and trade secrets,
trade practices, goodwill, clients, equipment, furniture, machinery, fixtures, supplies, inventory, existing contract and tangible personal property (the “Assets”). Our Board of Directors furthermore engaged in several analysis regarding the fair market value of our Assets based primarily upon a consideration of two valuations of a business using the tangible asset valuation method and the industry multiplier valuation method in connection with the offer and sale of our Assets, and determined that
the Board of Directors should be authorized to divest us of our travel business and related Assets at a price not less than the midpoint of those two valuation methods. Our Board of Directors determined that our Assets are to be valued at $57,489.
 
 Effective on April 20, 2009, our Board of Directors approved the execution of an asset purchase agreement dated April 20, 2009 (the “Agreement”) with Dirk Holzhauer, one of our shareholders, a director, and a former officer (the “Purchaser”). In accordance with the terms and provisions of the Agreement: (i) we sold
to the Purchaser the Assets for a purchase price of $57,489 (the “Purchase Price”); and (ii) as payment for the Assets, the Purchaser returned to us an aggregate of 191,631 shares of our common stock held of record by the Purchaser valued at $0.30 per share based upon the last trade price of $0.30 of our shares of common  stock as traded on the OTC Bulletin Board as of October 8, 2008.
 
 The Asset Purchase Agreement was subject to shareholder approval, which was provided. See “Part II. See “Part II. Item 4. Submission of Matters to a Vote of Security Holders.”
 
 On July 20, 2009, Dirk Holzhauer, a director and former officer of the Company, retired 23,953,875 shares of his common stock of the Company to acquire the Company’s travel related business assets effective July 1, 2009 pursuant to an Asset Purchase Agreement dated April 20, 2009.
 
 RESULTS OF OPERATION
  We have incurred recurring losses to date. Our financial statements have been prepared assuming that we will continue as a going concern and, accordingly, do not include adjustments relating to the recoverability and realization of assets and classification of liabilities that might be necessary should we be unable to continue in operation.
 
 We expect we will require additional capital to meet our long term operating requirements. We expect to raise additional capital through, among other things, the sale of equity or debt securities.
 
 Six Month Period Ended June 30, 2009 Compared to Six Month Period Ended June 30, 2008.
 
 Our comprehensive loss during the six month period ended June 30, 2009 was ($11,472) compared to a comprehensive loss of ($1,412) during the six month period ended June 30, 2008 (an increase of $10,060). This is primarily attributable to a decrease in gross sales during the six month period ended June 30, 2009 compared to the six month
period ended June 30, 2008, where we generated gross sales income of $125,698 and $139,405, respectively. Cost of sales increased during the six month period ended June 30, 2009 to $55,517 from $32,148 during the six month period ended June 30, 2008, resulting in net sales, or a gross margin, of $70,181 for the six month period ended June 30, 2009  compared to $107,258 for the same period in 2008.
 
 During the six month period ended June 30, 2009, we incurred general and administrative expenses of approximately $83,356 compared to $108,259 incurred during the six month period ended June 30, 2008 (a decrease of $24,903). The decrease in expenses is attributable to a reduction in payroll, professional, as well as general and administrative
expenses. General and administrative expenses generally include corporate overhead, financial and administrative contracted services, marketing, and consulting costs.
 
 Foreign currency translation adjustment costs incurred during the six month periods ended June 30, 2009 and June 30, 2008 of $1,703 and ($411), respectively, were recorded. This resulted in a comprehensive loss of ($11,472) or ($0.00) per share for the six month period ended June 30, 2009 compared to a comprehensive loss of ($1,412) or
($0.00) per share for the six month period ended June 30, 2008. The weighted average number of shares outstanding was 313,121,547 for the six month period ended June 30, 2009 compared to 300,000,000 for the six month period ended June 30, 2008 (taking into consideration the Forward Stock Split).
 
 Table of Contents
 11
 Three Month Period Ended June 30, 2009 Compared to Three Month Period Ended June 30, 2008.
 
 Our comprehensive loss during the three month period ended June 30, 2009 was ($13,560) compared to a comprehensive loss of ($3,618) during the six month period ended June 30, 2008 (an increase of $9,942). This is primarily attributable to a decrease in gross sales during the three month period ended June 30, 2009 compared to the three month
period ended June 30, 2008, where we generated gross sales income of $58,851 and $67,860, respectively. Cost of sales increased during the three month period ended June 30, 2009 to $22,553 from $17,447 during the three month period ended June 30, 2008, resulting in net sales, or a gross margin, of $36,298 for the three month period ended June 30, 2009  compared to $50,413 for the same period in 2008.
 
 During the three month period ended June 30, 2009, we incurred expenses of approximately $51,465 compared to $53,414 incurred during the three month period ended June 30, 2008 (a slight decrease of $1,949). General and administrative expenses incurred during the three month period ended June 30, 2009 compared to the three month period ended
June 30, 2008 decreased primarily due to the decrease in expenses associated with payroll and general and administrative.
 
 Foreign currency translation adjustment costs incurred during the three month periods ended June 30, 2009 and June 30, 2008 of $1,607 and ($617), respectively, were recorded. This resulted in a comprehensive loss of ($13,550) or ($0.0) per share for the three month period ended June 30, 2009 compared to a comprehensive loss of ($3,618)
or ($0.00) per share for the three month period ended June 30, 2008. The weighted average number of shares outstanding was 326,098,901 for the three month period ended June 30, 2009 compared to 300,000,000 for the three month period ended June 30, 2008 (taking into consideration the Forward Stock Split).
 
 LIQUIDITY AND CAPITAL RESOURCES
 
 As at June 30, 2009
 
 As at the six month period ended June 30, 2009, our current assets were $35,049 and our current liabilities were $112,847, which resulted in a working capital deficiency of ($77,798). As at the six month period ended June 30, 2009, current assets were comprised of: (i) $28,884 in cash; and (ii) $6,165 in accounts receivable (net of allowance
for doubtful accounts). As at the six month period ended June 30, 2009, current liabilities were comprised of: (i) $45,239 in accounts payable; (ii) $2,906 in accrued liabilities; (iii) $2,470 in payroll liabilities; (iv) $613 in sales tax payable; (v) $41,759 in shareholders’ loan; and (vi) $19,860 in current portion of long-term debt.
 
 As at the six month period ended June 30, 2009, our total assets were $159,681 compared to $59,954. This increase was primarily due to the acquisition of the three medical patents. See “Asset Purchase Agreement” above.
 
 As at the six month period ended June 30, 2009, our total liabilities were $112,847 comprised entirely of current liabilities. The increase in liabilities during the six month period ended June 30, 2009 from fiscal year ended December 31, 2008 was primarily due to an increase in accounts payable and shareholders’ loans. See “Material
Commitments”.
 
 Stockholders’ equity increased from ($35,680) for fiscal year ended December 31, 2008 to stockholders’ equity of $46,834 for the six month period ended June 30, 2009.
 
 Cash Flows from Operating Activities
 
 We have not generated positive cash flows from operating activities. For the six month period ended June 30, 2009, net cash flows used in operating activities was ($3,967), attributable primarily to our net loss of ($13,175). For the six month period ended June 30, 2008, net cash flows used in operating activities was ($10,680), attributable
primarily to an increases in accounts receivable.
 Table of Contents
 12
 
 Cash Flows from Investing Activities
 
 For the six month periods ended June 30, 2009 and June 30, 2008, net cash flows used in investing activities was $-0-.
 
 Cash Flows from Financing Activities
 
 We have financed our operations primarily from either advancements or the issuance of equity and debt instruments. For the six month period ended June 30, 2009, net cash flows provided from financing activities was $9,928 compared to $9,096 for the six month period ended June 30, 2008. Cash flows from financing activities for the six month
period ended June 30, 2009 consisted of $19,907 in borrowings on debt offset by ($9,979) in payments on debt. Cash flows from financing activities for the six month period ended June 30, 2008 consisted of $113,135 in borrowings on debt offset by ($104,040) in payments on debt.
 
 We expect that working capital requirements will continue to be funded through a combination of our existing funds, shareholder loans, and further issuances of securities. Our working capital requirements are expected to increase in line with the growth of our business.
 
 PLAN OF OPERATION AND FUNDING
 
 Existing working capital, further advances and debt instruments, and anticipated cash flow are expected to be adequate to fund our operations over the next six months. We have no lines of credit or other bank financing arrangements. Generally, we have financed operations to date through the proceeds of the private placement of equity and
debt instruments. In connection with our business plan, management anticipates additional increases in operating expenses and capital expenditures relating to the development, marketing and distribution of products relating to the Medical Patents. We intend to finance these expenses with further issuances of securities, and debt issuances. Thereafter, we expect we will need to raise additional capital and generate revenues to meet long-term operating requirements. Additional issuances of equity or convertible
debt securities will result in dilution to our current shareholders. Further, such securities might have rights, preferences or privileges senior to our common stock. Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, we may not be able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict our business operations.
 
 MATERIAL COMMITMENTS
 
 As of June 30, 2009, the total due to shareholders was $41,759. These loans are unsecured, non-interest beading and have no specific repayment terms. Imputed interest of $758 was calculated at a rate of 7.89% and recorded in additional paid-in capital at June 30, 2009.
 
 PURCHASE OF SIGNIFICANT EQUIPMENT
 
 We do not intend to purchase any significant equipment during the next twelve months.
 
 OFF-BALANCE SHEET ARRANGEMENTS
 
 As of the date of this Quarterly Report, we do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to
investors.
 
 GOING CONCERN
 
 The independent auditors' report accompanying our December 31, 2008 and December 31, 2007 financial statements contains an explanatory paragraph expressing substantial doubt about our ability to continue as a going concern. The financial statements have been prepared "assuming that we will continue as a going concern," which contemplates
that we will realize our assets and satisfy our liabilities and commitments in the ordinary course of business.
 
 Table of Contents
 13
 ITEM III. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
  Market risk represents the risk of loss that may impact our financial position, results of operations or cash flows due to adverse change in foreign currency and interest rates.
  Exchange Rate
  Our reporting currency is the Canadian Dollar. In the event we engage in business operations within the United States and outside of Canada, the fluctuation of exchange rates may have positive or negative impacts on our results of operations. However, since our business operations as of June 30, 2009 were primarily conducted within Canada,
revenue and expenses are denominated in Canadian Dollar, and the net income effect of appreciation and devaluation of the currency against the Canadian would be limited to our costs of engaging in business operations outside of Canada.
  Interest Rate
  Interest rates in Canada are generally controlled. Any potential future loans will relate mainly to the development and marketing of our Medical Patents and will be mainly short-term. However our debt may be likely to rise in connection with expansion of operations and if interest rates were to rise at the same time, this could become
a significant impact on our operating and financing activities. We have not entered into derivative contracts either to hedge existing risks of for speculative purposes.
  ITEM IV. CONTROLS AND PROCEDURES
 
 Evaluation of disclosure controls and procedures
 
 We have performed an evaluation under the supervision and with the participation of our management, including our Chief Executive Officer (CEO)/Chief Financial Officer (CFO), of the effectiveness of our disclosure controls and procedures, (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our
management, including our CEO/CFO, concluded that our disclosure controls and procedures were not effective as of June 30, 2009 to provide reasonable assurance that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.
 
 Management’s Annual Report on Internal Control Over Financial reporting
 
 Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Under the supervision and with the participation of our management, including our CEO/CFO, we evaluated the effectiveness of our internal control over financial reporting
as of June 30, 2009. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control-Integrated Framework.
 
 A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company's annual or interim financial statements will not be prevented or detected on a timely basis.  Management noted no changes
in the following material weaknesses stated in the 10-K:
 
 1.
As of June 30, 2009, we did not maintain effective controls over the control environment.  Specifically we have not developed and effectively communicated to our employees its accounting policies and procedures.  This has resulted in inconsistent practices.  Further, the Board of Directors does not currently
have any independent members and no director qualifies as an audit committee financial expert as defined in Item 407(d)(5)(ii) of Regulation S-B.  Since these entity level programs have a pervasive effect across the organization, management has determined that these circumstances constitute a material weakness.
 
 Table of Contents
 14
 
 2.
As of June 30, 2009, we did not maintain effective controls over financial statement disclosure. Specifically, controls were not designed and in place to ensure that all disclosures required were originally addressed in our financial statements.   Accordingly, management has determined that this control deficiency constitutes
a material weakness.
 
 3.
As of June 30, 2009, we did not maintain effective controls over receivables and accrued liabilities. Specifically, controls were not designed and in place to ensure that accrued liabilities were properly recorded and that receivables were evaluated for collectibility.   Accordingly, management has determined that this control
deficiency constitutes a material weakness.
 This Quarterly Report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to temporary rules of the SEC that permit us to provide only management’s
report in this Quarterly Report on Form 10-Q.
 
 Inherent Limitations on Effectiveness of Controls
 
 We believe that a controls system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. Our disclosure controls
and procedures are designed to provide reasonable assurance of achieving their objectives, and our CEO/CFO has concluded that these controls and procedures are effective at the “reasonable assurance” level.
 
 Changes in internal controls
 
 No significant changes were implemented in our internal controls over financial reporting during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
 
 AUDIT COMMITTEE
 
 Our Board of Directors has not established an audit committee nor do we have an audit committee financial expert. The respective role of an audit committee has been conducted by our Board of Directors. We are contemplating establishment of an audit committee during fiscal year 2009. When established, the audit committee's primary function
will be to provide advice with respect to our financial matters and to assist our Board of Directors in fulfilling its oversight responsibilities regarding finance, accounting, and legal compliance. The audit committee's primary duties and responsibilities will be to: (i) serve as an independent and objective party to monitor our financial reporting process and internal control system; (ii) review and appraise the audit efforts of our independent accountants; (iii) evaluate our quarterly financial performance
as well as its compliance with laws and regulations; (iv) oversee management's establishment and enforcement of financial policies and business practices; and (v) provide an open avenue of communication among the independent accountants, management and our Board of Directors.
  PART II. OTHER INFORMATION
 
 ITEM 1. LEGAL PROCEEDINGS
 
 Management is not aware of any legal proceedings contemplated by any governmental authority or any other party involving us or our properties. As of the date of this Quarterly Report, no director, officer or affiliate is (i) a party adverse to us in any legal proceeding, or (ii) has an adverse interest to us in any legal proceedings. Management
is not aware of any other legal proceedings pending or that have been threatened against us or our properties.
 
 ITEMIA. RISK FACTORS
 
 No report required.
 
 Table of Contents
 15
 ITEM2. UNREGISTERED SALES OF SECURITIES AND USE OF PROCEEDS
 
 Effective on April 15, 2009, our Board of Directors approved the execution of the Asset Purchase Agreement with the Seller. On April 20, 2009, the right, title and interest to the Medical Patents was transferred by Phoinos Oxford to us and we issued the 250,000 Pre-Forward Stock Split (31,250,000 Post-Forward Stock Split) shares of our
restricted stock to Phoinos Oxford as consideration for the Medical Patents.
  Under the terms and provisions of the Asset Purchase Agreement and the Escrow Agreement, we placed in escrow the 250,000 Pre-Forward Stock Split (31,250,000 Post-Forward Stock Split) shares of our restricted common stock in escrow (the “Escrow Shares”). The Escrow Shares are to be subsequently transferred to Phoinos Oxford in
ten (10) quarterly installments and Phoinos Oxford agreed to assign the voting rights of the Escrow Shares to Global. The Escrow Shares are being held by Global as escrow agent and 10% of the Escrow Shares will be transferred quarterly from Global to Phoinos Oxford in accordance with the terms of the Escrow Agreement.
  The issuance of the shares to the Seller was in reliance on Rule 903 of Regulation S promulgated under the Securities Act of 1933, as amended. The securities issued in accordance with the Asset Purchase Agreement have not been registered under the Securities Act or under any state securities laws and may not be offered or sold without registration
with the United States Securities and Exchange Commission or an applicable exemption from the registration requirements. There were no finders' fees or commission payable by us upon consummation of the transaction.
  ITEM 3. DEFAULTS UPON SENIOR SECURITIES
  No report required.
 
 ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
 
 On April 20, 2009, our Board of Directors authorized and approved, subject to shareholder approval, certain corporate actions, which the Board of Directors deemed to be in our best interests and our shareholders. Our Board of Directors further authorized the preparation and circulation of an information statement dated April 21, 2009 (the
“Information Statement”) and a shareholders' consent to certain shareholders holding a majority of the total issued and outstanding shares of our common stock (the “Consenting Shareholders”). The preliminary Information Statement was filed with the Securities and Exchange Commission on April 21, 2009 and a definitive Information Statements was filed with the Securities and Exchange Commission on July 1, 2009 and subsequently provided to our shareholders.
 
 The matters upon which action was taken was: (i) approval of the divesture and sale of the our travel related products and assets in accordance with the terms and provisions of the Agreement with Dirk Holzhauer; (ii) approval of the amendment (the “Name Change Amendment”) to our Articles of Incorporation, as amended (the “Articles
of Incorporation”) to effectuate a change in our name of the Corporation (the “Name Change”) to Genova Biotherapeutics Inc.; (iii) approval of an amendment (the “Change in Capital Structure Amendment”) to our Articles of Incorporation to amend our authorized capital structure from 65,000,000 shares of common stock with a par value of $0.001 per share to 1,000,000,000 shares of common stock with a par value $0.00001 per share; and (iv) approval and ratification of the appointment
of the current members of our Board of Directors and to duly appoint  Hyunho Jin as a member of our Board of Directors to serve until his successor is duly appointed.
 
 The above actions were approved by our Board of Directors and the Consenting Holders on April 20, 2009 and April 21, 2009 respectively. Accordingly, we have secured the necessary authorization for the above actions.
 
 Table of Contents
 16
 ITEM5. OTHER INFORMATION
 
 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.
 
 On April 10, 2009, Dirk Holzhauer, our sole director, appointed Mr. Aaron Whiteman to join the Board to fill a vacancy created by the resignation, in September 2008 of the only other member of the Board of Directors. Mr. Whiteman accepted the appointment on April 10, 2009.
 
 On April 13, 2009, our Board of Directors appointed Mr. Aaron Whiteman as our President/Chief Executive Officer and Treasurer/Chief Financial Officer, Dr. John Savin as our Vice President and Mr. Hyunho Jin as our Secretary. Mr. Whiteman, Dr. Savin, and Mr. Jin all accepted their respective appointments on April 13, 2009. On April 13, 2009,
Mr. Dirk Holzhauer, our incumbent President, Vice President, Treasurer and Secretary, resigned. The resignation did not involve any disagreement with us. Mr. Holzhauer will remain one of our directors.
 
 On April 21, 2009, in accordance with the approval by the Consenting Holders and the provisions of the Information Statement, Hyunho Jin was appointed to our Board of Directors.
 
 Therefore, as a result of the above changes, our officers and directors are as follows:
  Name

TitleAaron Whiteman

President/Chief Executive Officer/Treasurer/Chief FinancialOfficer and a directorJohn Savin

Vice PresidentHyunho Jin

Secretary and a directorDirk Holzhauer

Director  Management Biographies
 
 Aaron Whiteman.Mr. Aaron Whiteman holds a Bachelors of Law Degree from Oxford University and an MBA from the London School of Economics.  Most recently, he served as a Vice President of Reliance Biotech, an Indian medical research company, responsible for business development
and expansion into the European, Middle Eastern, and African regions.  Prior to that, from May 2002 through May 2007, Aaron Whiteman was a Vice President of Viranative AB, where he was responsible for promotion of the company’s products to strategic partners in the Sub-Saharan region. During his tenure, he successfully secured licensing agreements and commercial alliances with pharmaceutical giants Pharmacia (Upjohn), Astra Zeneca, and Glaxo Smith Kline.  He has also held various
executive, board, and advisory positions in the telecommunications industry.
 
 John Savin.Dr. Savin was the chief executive officer of Physiomics plc, a cancer research and simulation company he founded in 2001, which was quoted on the London Alternative Investment Market in 2004. As the chief executive officer, he created a multi-disciplinary research and development
team, raised equity funding, marketed to major pharmaceutical and biotech companies in Europe and the United Sates, developedsales pipelines, and established a global marketing and technology strategic alliance with Bayer AG. Dr. Savin left Physiomics in 2006 to found Wendover Technology, which provides consulting services to the biotechnology industry.Wendover Technology services include
investment reports, due diligence on mergers and acquisitions, strategic planning, project management, and negotiating licensing agreements. Prior to Physiomics, Dr. Savin was a top-rated investment analyst in the pharmaceutical and biotech sector in London. He has also worked as a high-level consultant and has an industry background in international marketing of life science products and DNA diagnostics. Dr. Savin was awardeda Ph.D. in organic chemistry
from Nottingham University and has an MBA with a distinction in international business and corporate strategy. He has been a director of various companies including Biotechconvergence, Wendover Technology, Zetagen and Greig Middleton & Co.
 
 Hyunho Jin.Following three years of compulsory military service, Mr. Hyunho Jin attended Youngjin College in Seoul, Korea where he received a management diploma. He was hired by the Hansung office of BTM Services Corp., a management consulting company, where he was responsible for
business development of their regional office. He held that position for two years before being moved, in May 2000, to the Bohun office, where he was responsible for international business development, specifically expansion into South East Asia.
 
 Table of Contents
 17
 Dirk Holzhauer.After completing two years of service in the German army, Mr. Holzhauer attended Werner-von-Siemenns-Berufskolleg in Cologne where he received a Bachelors Degree in Business Economics.  This was followed by several business ventures in Germany before he emigrated
to Canada in 1996.  Since then he has served as an officer and director of both public and private companies in the United States and Canada, including his position as founding officer, director, and shareholder of Kinder Travel Inc. since 2005.  Mr. Holzhauer is a citizen of Germany and a resident of Canada.
  ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
  Exhibits10.01
Asset Purchase Agreement dated April 20, 2009 between Kinder Travel Inc. and Dirk Holzhauer. (1)10.2
Asset Purchase Agreement dated April 15, 2009 between Kinder Travel Inc. andPhoinos Oxford Lifesciences Limited. (2)31.1
Certification of Chief Executive Officer pursuant to Securities Exchange Act of1934 Rule 13a-14(a) or 15d-14(a).31.2
Certification of Chief Financial Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a).32.1
Certifications pursuant to Securities Exchange Act of 1934 Rule 13a-14(b) or 15d-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002.(1)
Incorporated by reference to the exhibit filed with our Current Report on Form 8-K filed with the Securities and Exchange Commission on April 21, 2009.(2)
Incorporated by reference to the exhibit filed with our Current Report on Form 8-K filed with the Securities and Exchange Commission on April 15, 2009.
  18
 SIGNATURES
 
 In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
  GENOVA BIOTHERAPEUTICS INC.Dated: August 10, 2009
By:
/s/ Aaron WhitemanAaron Whiteman, President and Chief Executive Officer
 Dated: August 10, 2009
By:
/s/ Aaron WhitemanAaron Whiteman, President and Chief Executive Officer   19